ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,738.52
      -1.78%
      US Tech 100
      19,620.80
      -2.29%
      Dow Jones
      42,579.08
      -0.99%
      Brent Oil
      69.34
      0.00%
      Bitcoin
      87,337.62
      -2.89%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. AcelRX Pharmaceuticals Inc (ACRX) Quote

      AcelRX Pharmaceuticals Inc

      AcelRX Pharmaceuticals Inc (ACRX)

      NASDAQ
      0.86
      0.00
      (0.00%)
      Closed March 06 4:00PM
      Delayed by 15 minutes
      0.00
      0.00
      (0.00%)
      After Hours: -
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      0.86
      Bid
      0.861
      Ask
      0.89
      Volume
      -
      0.00 Day's Range 0.00
      0.00 52 Week Range 0.00
      Market Cap
      14.579M
      Previous Close
      0.86
      Open
      -
      Last Trade
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      -
      Shares Outstanding
      16,952,000
      Dividend Yield
      -
      PE Ratio
      -0.79
      Earnings Per Share (EPS)
      -1.09
      Revenue
      651k
      Net Profit
      -18.4M

      About AcelRX Pharmaceuticals Inc

      AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-... AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-02 and ARX-03. The majority of its revenue is generated from DSUVIA product sales in the United States. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      talphera.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -

      Ask ADVFN Intelligence (AI)

      ACRX Latest News

      More News

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      June 24 2024
      ACRX (0.00%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      June 24 2024
      ACRX (0.00%)

      Form ARS - Annual Report to Security Holders
      Edgar (US Regulatory)
      April 29 2024
      ACRX (0.00%)

      Form DEF 14A - Other definitive proxy statements
      Edgar (US Regulatory)
      April 29 2024
      ACRX (0.00%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      April 19 2024
      ACRX (0.00%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      March 21 2024
      ACRX (0.00%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      March 15 2024
      ACRX (0.00%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      March 12 2024
      ACRX (0.00%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      January 09 2024
      ACRX (0.00%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000CS
      40000000CS
      120000000CS
      260000000CS
      520000000CS
      1560000000CS
      2600000000CS

      ACRX - Frequently Asked Questions (FAQ)

      What is the current AcelRX Pharmaceuticals share price?
      The current share price of AcelRX Pharmaceuticals is $ 0.86
      How many AcelRX Pharmaceuticals shares are in issue?
      AcelRX Pharmaceuticals has 16,952,000 shares in issue
      What is the market cap of AcelRX Pharmaceuticals?
      The market capitalisation of AcelRX Pharmaceuticals is USD 14.58M
      What is the 1 year trading range for AcelRX Pharmaceuticals share price?
      AcelRX Pharmaceuticals has traded in the range of $ 0.00 to $ 0.00 during the past year
      What is the PE ratio of AcelRX Pharmaceuticals?
      The price to earnings ratio of AcelRX Pharmaceuticals is -0.79
      What is the cash to sales ratio of AcelRX Pharmaceuticals?
      The cash to sales ratio of AcelRX Pharmaceuticals is 22.4
      What is the reporting currency for AcelRX Pharmaceuticals?
      AcelRX Pharmaceuticals reports financial results in USD
      What is the latest annual turnover for AcelRX Pharmaceuticals?
      The latest annual turnover of AcelRX Pharmaceuticals is USD 651k
      What is the latest annual profit for AcelRX Pharmaceuticals?
      The latest annual profit of AcelRX Pharmaceuticals is USD -18.4M
      What is the registered address of AcelRX Pharmaceuticals?
      The registered address for AcelRX Pharmaceuticals is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
      What is the AcelRX Pharmaceuticals website address?
      The website address for AcelRX Pharmaceuticals is talphera.com
      Which industry sector does AcelRX Pharmaceuticals operate in?
      AcelRX Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      PSTVPlus Therapeutics Inc
      $ 1.46
      (317.14%)
      		359.59M
      AGMHAGM Group Holdings Inc
      $ 0.213
      (108.21%)
      		694.71M
      LZMHLZ Technology Holdings Ltd
      $ 9.79
      (33.56%)
      		590.5k
      TNXPTonix Pharmaceuticals Holding Corporation
      $ 14.62
      (33.39%)
      		16.07M
      GVVisionary Holdings Inc
      $ 4.89
      (32.34%)
      		135.24M
      BLNEEastside Distilling Inc
      $ 0.7846
      (-89.40%)
      		12.01k
      ACONAclarion Inc
      $ 1.5501
      (-77.86%)
      		51.24M
      ELABPMGC Holdings Inc
      $ 0.7132
      (-42.02%)
      		1.48M
      SNBRSleep Number Corporation
      $ 7.49
      (-41.89%)
      		4.52M
      CCLDCareCloud Inc
      $ 2.0904
      (-33.00%)
      		1.22M
      AGMHAGM Group Holdings Inc
      $ 0.213
      (108.21%)
      		694.71M
      PSTVPlus Therapeutics Inc
      $ 1.46
      (317.14%)
      		359.59M
      NVDANVIDIA Corporation
      $ 110.57
      (-5.74%)
      		321.25M
      GVVisionary Holdings Inc
      $ 4.89
      (32.34%)
      		135.24M
      TSLLDirexion Daily TSLA Bull 2X Trust ETF
      $ 10.75
      (-11.38%)
      		134.95M

      Discussion

      View Full Feed
      Milesblue42 Milesblue42 2 minutes ago
      Ronn Bashing Investors with Dilution? 396MillionShares??

      .0001 INCOMING

      396 million shares traded today but closed at .0002? Must be that Delirious Imaginary Basher Index huh
      RONN
      sam1933 sam1933 2 minutes ago
      The deeper I get into $HBAR, the more convinced I am that it’s the future of blockchain.
      https://hedera.com/ecosystem
      https://i.redd.it/idh1qfkuctia1.jpg
      HBAR
      farml1234 farml1234 2 minutes ago
      Interview with the CEO
      https://www.northernminer.com/news/jv-qa-how-dundee-sustainable-technologies-eases-adoption-of-green-processes/1003875954/

      interesting
      DST
      kund kund 2 minutes ago
      You invest with half the information and keep believing in this POS—typical WGT crowd...No wonder Misleading has no shame in telling lies.
      AVXL
      doccjc doccjc 2 minutes ago
      Again SC8, I don't have IM on IHub . 
      The reason I think  is because your posts are far from objective . I hope that helps .
      Go RDGL
      RDGL
      Hoskuld Hoskuld 3 minutes ago
      Well that is not what was done in AD. The AD P2b was extended by 10% - and the schizophrenia trial would have to be extended by 800%. That would mean they would not be able to unblind for another year. AND would still have to run another P3 AFTER that readout. That strategy would delay 3-71 by a
      AVXL
      Wayne R Wayne R 3 minutes ago
      Ditto, hard boiled, soft boiled, poached, fried, omelet etc.

      I knew someone who worked in an egg grading station in Dashwood, Ontario. I'd get these huge eggs for free, their problem was they had 2 and sometimes 3 yokes, so not of any value on the market. Strange.

      Ate
      ShawnP123 ShawnP123 4 minutes ago
      NVIDIA's outlook for the first quarter of fiscal 2026 is as follows: Revenue is expected to be $43.0 billion, plus or minus 2%. GAAP and non-GAAP gross margins are expected to be 70.6% and 71.0%, respectively, plus or minus 50 basis points.Feb 26, 2025
      Source: https://www.shacknews.com/articl
      NVDA
      StarryComet61 StarryComet61 4 minutes ago
      The SS is interesting to me. In the most recent form 3 filing, Trieu Vuong owns directly 93M shares..Autotelic owns 16M and his own spouse owns 6M of course these are all rounded, the total shares owned is almost 117 M . The number of shares held at DTC per OTC markets is 115M,.almost 116M. That mea
      OTLC
      NASDAQ2020 NASDAQ2020 5 minutes ago
      Did you mean a dead customer/patient ?
      RDGL
      100lbStriper 100lbStriper 6 minutes ago
      gail is only capable of spending hongs free shares. she couldnt arrange a sit down with a real candidate if she tried!!! and hong never says a word about him talking to anyone......... but as far as business is concerned we have some revenue but have to give suji highly discounted shares to get mone
      NLST
      $7.00 or Nothing $7.00 or Nothing 6 minutes ago
      Issue in your head only.

      That “issue” made us rich
      ELTP
      BDEZ BDEZ 7 minutes ago
      Exactly...
      Waynewayne Waynewayne 7 minutes ago
      Do tell!
      HMBL
      JustJack JustJack 8 minutes ago
      No, I do not know. You are giving me more credit than I deserve but shareholders may want to know. 

      Just don't want people to think, from your post, that it is all sunshine and roses. 
      AITX
      dia76ca dia76ca 9 minutes ago
      WOW! That is really interesting! But of course we must wait to see if that same benefit applies to humans. But if it does apply to Schizophrenia in humans would it also apply to Alzheimer's, Parkinson's etc. etc. Anavex 3-71 is so much more powerful than blarcamesine that there is much to be learned
      AVXL
      Truenorth2016 Truenorth2016 9 minutes ago
      Looks like they are trying to have everything in place prior to news
      GCAN
      3331 3331 9 minutes ago
      BIEL GONNA RUN LIKE 2021!
      Scholars have always discussed the notion that history repeats itself.
      https://microcapdaily.com/exciting-week-for-bioelectronics-corp-otcpink-biel/124825/
      Jack_of_All_Trades Jack_of_All_Trades 9 minutes ago
      Awesome close!!! Congratulations to everyone who ignored the noise!

      RDAR
      RDAR
      ElectricJester54 ElectricJester54 10 minutes ago
      I don't have ihub premium so I can answer here. Audit for ZHUD is an answer I don't have but you could probably ask Cohen directly. Only audit I for sure know they have discussed on here/X/instagram is for AZRH but I assume if they plan to uplist here as well then it will be required. But you can re
      AZRH ZHUD
      3331 3331 11 minutes ago
      BIEL SQUEEZE!
      Samuel J Samuel J 11 minutes ago
      I can vouch Dino has a good and healthy amount of shares. I know my brother too well. He's holding.
      AZRH
      3331 3331 12 minutes ago
      b]BIEL GONNA RUN LIKE 2021!
      Involuntary-Recluse Involuntary-Recluse 13 minutes ago
      1000 pardons my good man, just keeping the old CLHI high alive as a starting point ;-)
      CLHI
      3331 3331 13 minutes ago
      b]BIEL GONNA RUN LIKE 2021!

      Your Recent History

      NASDAQ
      ACRX
      AcelRX Pharmaceuticals
      LSE
      CSSG
      Croma Security Solutions
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads